莫比可治疗类风湿关节炎的疗效观察

Clinical Evaluation of Mobic[meloxicam] in Treatieg Rheumatold Arthrltls and Osteoarthritis

目的 观察新型非甾体消炎止痛药莫比可治疗类风湿关节炎和骨关节炎的疗效和不良反应。方法:80例类风湿关节炎病人随机分为治疗组50例,对照组30例。40例骨关节炎病人分为治疗组20例,对照组20例。治疗组服莫比可7.5mg,po.bid×4wk;对照组服双氯芬酸钠25mg,po,tid×4wk。结果:在治疗组中类风湿关节炎组和骨关节炎组的疗效分别为86％和80％,对照组为83.33％和80％,两组无显著差异(P>0.05)。不良反应发生率治疗组和对照组分别为13.75％和30％,治疗组明显低于对照组(P<0.05)。结论:莫比可是一种安全有效的新型非甾体消炎止痛药。

To observe the efficacy and safety of the new NSAIDs meloxicam in treating rheumatoid arthritis and osteoarthritis. METHODS:Eighty patients with rheumatoid arthritis were randomly divided into 2 groups, 50 patients of treatment group were treated with meloxican 7.5mg, po. bid, and 30 patients of control group were treated with diclofenac sodium 25mg, po, tid. Fouty patients with osteoarthritis were also divided into 2 groups, 20 patients were treated with meloxicam 7.5mg, po, bid, and the other patients were treated with diclofenac sodium 25mg, po, tid. RESULTS: The efficacy rates of meloxicam and diclofenac sodium in rheumatoid arthritis and osteoarthritis group were 86.00%,80,00%and 83.3396.80.00% (P>0.05).The rates of adverse reaction were respectively 13.75%and 3096.The rates of adverse reaction of meloxicam was lower than diclofenac sodium(P<0.05) .CONCLUSION: Meloxicam is efficacious and safe in treating cheumatoid arthritis and rsteoarthritis.